We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company ...

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a ...

Disney surges, Uber stumbles, and AMD gains as US stocks edge higher today. Traders focus on Fed policy signals and sector ...

Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents.

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

Sarepta Therapeutics Inc (SRPT) reports significant revenue growth despite facing operational and reputational challenges in ...